Drug – bio-affecting and body treating compositions – Inorganic active ingredient containing – Carbonate
Reexamination Certificate
2007-10-31
2009-11-17
Arnold, Ernst V (Department: 1616)
Drug, bio-affecting and body treating compositions
Inorganic active ingredient containing
Carbonate
C514S492000
Reexamination Certificate
active
07618656
ABSTRACT:
A method for treating hyperphosphatemia using lanthanum carbonate, including analytically determining the amount of an impurity in the lanthanum carbonate sample is provided. This X-ray diffraction method preferably uses the Rietveld refinement.
REFERENCES:
patent: 4246246 (1981-01-01), Nakamura et al.
patent: 5045289 (1991-09-01), Fernando et al.
patent: 5503815 (1996-04-01), Ishii et al.
patent: 5562921 (1996-10-01), Sherman et al.
patent: 5853758 (1998-12-01), Lo
patent: 5968976 (1999-10-01), Murrer et al.
patent: 6055293 (2000-04-01), Secrest
patent: 6160016 (2000-12-01), DeLuca
patent: 6281503 (2001-08-01), Lazarev et al.
patent: 6678347 (2004-01-01), Kozaczek et al.
patent: 6790343 (2004-09-01), Wang et al.
patent: 7078059 (2006-07-01), Atherton et al.
patent: 7184517 (2007-02-01), Kern et al.
patent: 7256049 (2007-08-01), Bennett et al.
patent: 2001/0014352 (2001-08-01), Batra et al.
patent: 2003/0121824 (2003-07-01), Wang et al.
patent: 2003/0198997 (2003-10-01), Von Dreele
patent: 2004/0161474 (2004-08-01), Moerck et al.
patent: 2005/0054077 (2005-03-01), Bennett et al.
patent: 2006/0002837 (2006-01-01), Moerck et al.
patent: 2006/0083791 (2006-04-01), Moerck et al.
patent: 2006/0121127 (2006-06-01), Ferdinando et al.
patent: 2006/0134225 (2006-06-01), Moerck et al.
patent: 2006/0153932 (2006-07-01), Ferdinando et al.
patent: 62145024 (1987-06-01), None
patent: WO-9630029 (1996-10-01), None
patent: WO 00/79252 (2000-12-01), None
patent: WO-03053432 (2003-07-01), None
Barnett, Stephanie, “X-Ray Powder Diffraction Studies of Ettringite and Related Systems,” Staffordshire University, 6 pages, http://web.archive.org/web/20040611022250/http://www.geocities.com/j—bunford/ (accessed Aug. 3, 2007).
Litteer, Brian et al., “Increasing Application of X-Ray Powder Diffraction in the Pharmaceutical Industry,” American Laboratory, Jun. 2005, 37(12):22-23.
“Lanthanum Carbonate,” MDXexchange, Dec. 2004, 7 pages, http://www.micromedex.com/products/updates/drugdex—updates/de/lanthanum.html (accessed Aug. 3, 2007).
Aldrich Handbook of Fine Chemicals and Laboratory Equipment, 2000-2001, p. 1001, www.sigma-aldrich.com.
International Search Report and Written Opinion mailed Feb. 15, 2008, which issued during the prosecution of International Patent Application No. PCT/US 07/61461 (7 pages).
European Patent Office Action dated Feb. 20, 2008, which issued during the prosecution of European Patent Application No. 06 252 404.6, and which corresponds to the present application (4 pages).
Ansel, Howard et al., “Pharmaceutical Dosage Forms and Drug Delivery Systems,” 7th Ed., Lippincott Williams & Williams, Philadelphia, pp. 217-218, 1999.
“FDA Approves Fosrenol (R) to Reduce Phosphorous Levels in End-Stage Renal Disease Patients,” RedOrbit News, Oct. 27, 2004, 11 pages http://www.redorbit.com/modules
ews/tools.php?tool=print&id=98076 (accessed Feb. 5, 2009).
Hutchison, Alastair J. et al., “Long-Term Efficacy and Safety Profile of Lanthanum Carbonate: Results for up to 6 Years of Treatment,” Nephron Clinical Practice 110, pp. c15-c23, 2008.
“ICH Harmonised Tripartite Guideline: Impurities in New Drug Products Q3B(R2),” International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, Step 4 Version, Jun. 2, 2006, 15 pages http//www.ich.org/cache/compo/276-254-1.html.
Jonasson, R. G. et al., “Solubilities of some hydrous REE phosphates with implications for diagenesis and sea water concentrations,” Geochimica et Cosmochimica Acta, vol. 49, pp. 2133-2139, Jul. 12, 1985.
Letter (Redacted) from Barr Laboratories, Inc. to Shire Biochem Inc., “Notice of ANDA . . . Concerning Lanthanum Carbonate . . . With Paragraph IV Certification Concerning U.S. Patent Nos. 5,968,976, 7,381,428, and 7,465,465,” Feb. 2, 2009, 75 pages.
Letter (Redacted) from Mylan Inc. to Shire plc et al., “Fosrenol-Lanthanum Carbonate Chewable Tablets (500 mg, 750 mg and 1000 mg), U.S. Patent Nos. 7,465,465; 7,381,428; 5,968,976: Notice of Paragraph IV Certification,” Feb. 4, 2009, 48 pages.
Letter (Redacted) from Natco Pharma Limited to Shire Development, Inc. et al., “Lanthanum Carbonate (Equivalent to 500 mg, 750 mg and 1000 mg Lanthanum) Chewable Tablets—Fosrenol® —LVM Reference: 263909,” Feb. 13, 2009, 15 pages.
Mineely, Patrick J. et al., “Molten Potassium Pyrosulfate: Reactions of Lanthanum Metal and Six of its Compounds,” Aust. J. Chem., 40, 1309-1314, 1987.
Oda, Toshiyuki, “Studies on Crystal Waters of Lanthanum Carbonates,” Research Bull. Fac. Edu., Oita University 4(5), (Nat. Sci.), 1975, 5 pages.
“Pharmaceutical Dosage Forms: Tablets,” 2nd Ed., vol. 1, Marcel Dekker, Inc., New York, 1989, 53 pages.
Rowe, Raymond C. et al., “Handbook of Pharmaceutical Excipients,” 5th Ed., London, Aug. 2005, 8 pages.
Shire Canada Inc. et al.v.Barr Laboratories, Inc., “Amended Complaint for Patent Infringement,” In the United States District Court for the Southern District of New York, Cause No. 09-Civ-2380 (PGG), Apr. 3, 2009, 15 pages.
Shire Canada Inc. et al.v.Mylan Inc. et al., “Complaint for Patent Infringement,” In the United States District Court for the Southern District of New York, Cause No. 09 CIV 2555, Mar. 19, 2009, 20 pages.
Shire Canada Inc. et al. v.Natco Pharma Limited, “Complaint for Patent Infringement,” In the United States District Court for the Southern District of New York, Cause No. 09 CIV 3165, Apr. 1, 2009, 13 pages.
Yanagihara, Naohisa et al., “Synthesis of Lanthanide Carbonates,” J. of the Less-Common Metals, 167,223-232, 1991, 10 pages.
Mzareulishvili, N. et al., “Study of interaction of lanthanum nitrate with alkali metal ammonium carbonates,” Chem. Abstracts, 104(26), No. 236218u, 1986.
Preiss, Josef et al., “Üer die Karbonate der seltenen Erden. I. Bildungsverhältnisse und Hydrolyse der Ceriterdkarbonate,” Zeitschrift für Anorganische und Allgemaine Chemie, 131, 275-286, Aug. 22, 1923.
Sklyarenvo et al., “Application of Thernnogravimetry in Analytical Chemistry. Report 3. Thermogravimetry Study of Lanthanum Carbonate,” J. Analytical Chemistry - Academy of Science of the USSR, vol. XVI, Issue 4, 1961.
“Long-Term Effect of Lanthanum Carbonate on Bone - Study SPD405-309,” Shire Pharmaceutical Development, ClinicalTrials.gov, Aug., 2005, 3 pages http://clinicaltrials.gov/ct2/show/study/NCT00557323?term=spd405-309 (accessed Mar. 17, 2009).
Bates Simon
Hallenbeck Donald
Arnold Ernst V
Darby & Darby P.C.
Olson Lydia G.
Shire International Licensing B.V.
LandOfFree
Method for use of lanthanum carbonate pharmaceutical... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for use of lanthanum carbonate pharmaceutical..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for use of lanthanum carbonate pharmaceutical... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4078691